The Food and Drug Administration placed a clinical hold on Sarepta Therapeutics' investigational gene-therapy clinical trials for limb-girdle muscular dystrophy, a group of genetic disorders that cause muscles to weaken and atrophy.

Sarepta Therapeutics said it will continue shipping its gene therapy Elevidys for Duchenne muscular dystrophy patients despite an FDA request to pause distribution following multiple patient deaths. The FDA’s request July 18 came after Sarepta confirmed the death of a third patient from acute liver failure tied to its gene therapy programs.